Breast cancer and cardiovascular outcomes

Project Summary Title and Description

Title
Breast cancer and cardiovascular outcomes
Description
Q1: What is the risk for the development of cardiovascular outcomes in patients with breast cancer compared to those in the general population? Q2: What are the incidence rates of cardiovascular diseases among patients diagnosed with breast cancer?
Attribution
Semey Medical University, Semey, Kazakhstan; Bursa Education and Research Hospital, Health Science University, Bursa, Turkey; Faculty of Medicine, University of Zawia, Az Zawiyah, Libya Ege University, School of Medicine, Department of Cardiology Larner College of Medicine, University of Vermont, Burlington , Vermont, USA; Cardiovascular Department, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia; Keele Cardiovascular Research Group, Keele University, the United Kingdom.
Authors of Report
Dr Akhmetzhan Galimzhanov. Semey Medical University Dr Abdulmueti Alhadi. Faculty of Medicine, University of Zawia, Az Zawiyah, Libya Dr Han Naung Tun. Larner College of Medicine, University of Vermont, Burlington , Vermont, USA Dr Meral Kayikcioglu. Ege University, School of Medicine, Department of Cardiology Dr Mirvat Alasnag. Cardiovascular Department, King Fahd Armed Forces Hospital, Jeddah Dr Erhan Tenekecioglu. Bursa Education and Research Hospital, Health Science University Professor Mamas Mamas. Keele Cardiovascular Research Group, Keele University
Methodology description
Systematic Review
PROSPERO
CRD42022298741
DOI
N/A
Notes
All data were entered prospectively. The New-Castle-Ottawa scale was used for the risk of bias assessment
Funding Source
None

Key Questions

1. What is the risk of development of cardiovascular diseases in patients diagnosed with breast cancer as compared to the general population?
2. What are the incidence rates of cardiovascular diseases among patients diagnosed with breast cancer?

Associated Extraction Forms

Type
Standard

Associated Studies (each link opens a new tab)

Title Authors Year
Late mortality in people with cancer: a population-based Australian study. Koczwara Bogda; Meng Rosie; Miller Michelle D; Clark Robyn A; Kaambwa Billingsley; Marin Tania; Damarell Raechel A; Roder David M 2021
Incidence of atrial fibrillation in conjunction with breast cancer. D'Souza Maria; Smedegaard Lærke; Madelaire Christian; Nielsen Dorte; Torp-Pedersen Christian; Gislason Gunnar; Schou Morten; Fosbøl Emil 2019
Major Adverse Cardiovascular Events after Treatment in Early-stage Breast Cancer Patients Receiving Hormone Therapy. Chou Ying-Hsiang; Huang Jing-Yang; Kornelius Edy; Chiou Jeng-Yuan; Huang Chien-Ning 2020
Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors. Chang Jee Suk; Shin Jaeyong; Park Eun-Cheol; Kim Yong Bae 2019
Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group. Lee Jihyoun; Hur Ho; Lee Jong Won; Youn Hyun Jo; Han Kyungdo; Kim Nam Won; Jung So-Youn; Kim Zisun; Kim Ku Sang; Lee Min Hyuk; Han Se-Hwan; Jung Sung Hoo; Chung Il Yong 2020
Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors. Boekel Naomi B; Schaapveld Michael; Gietema Jourik A; Russell Nicola S; Poortmans Philip; Theuws Jacqueline C M; Schinagl Dominic A X; Rietveld Derek H F; Versteegh Michel I M; Visser Otto; Rutgers Emiel J T; Aleman Berthe M P; van Leeuwen Flora E 2016
Risk of death from cardiovascular disease following breast cancer in Southeast Asia: a prospective cohort study. Gernaat S A M; Ho P J; Rijnberg N; Lee S C; Lim S H; Yap Y S; Grobbee D E; Hartman M; Verkooijen H M 2017
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Ligibel Jennifer A; James O'Malley A; Fisher Maxine; Daniel Gregory W; Winer Eric P; Keating Nancy L 2012
Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation. A population-based study. van Herk-Sukel Myrthe P P; Shantakumar Sumitra; Kamphuisen Pieter W; Penning-van Beest Fernie J A; Herings Ron M C 2011
Favorable cardiac risk among elderly breast carcinoma survivors. Lamont Elizabeth B; Christakis Nicholas A; Lauderdale Diane S 2003
Ethnic differences in cardiovascular morbidity and mortality among patients with breast cancer in the Netherlands: a register-based cohort study. Deen Laura; Buddeke Josefien; Vaartjes Ilonca; Bots Michiel L; Norredam Marie; Agyemang Charles 2018
Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Bradbury Brian D; Lash Timothy L; Kaye James A; Jick Susan S 2005
Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: A population-based Danish Breast Cancer Group study. Milo Marie Louise Holm; Thorsen Lise Bech Jellesmark; Johnsen Søren Paaske; Nielsen Kirsten Melgaard; Valentin Jan Brink; Alsner Jan; Offersen Birgitte Vrou 2021
Second cancer, breast cancer, and cardiac mortality in stage T1aN0 breast cancer patients with or without external beam radiation therapy: a national registry study. Ye Jason C; Yan Weisi; Christos Paul; Nori Dattatreyudu; Chao Kun-San C; Ravi Akkamma 2015
Heart-related mortality after postoperative breast irradiation in patients with ductal carcinoma in situ in the contemporary radiotherapy era. Lim Yu Jin; Koh Jaemoon 2021
Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Choi Jung Yoon; Cho Eun Young; Choi Yoon Ji; Lee Jeong Hyeon; Jung Seung Pil; Cho Kyu Ran; Kim Chul Yong; Kim Yeul Hong; Park Kyong Hwa 2018
Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Jagsi Reshma; Griffith Kent A; Koelling Todd; Roberts Rachel; Pierce Lori J 2007
Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. Qin Angel; Thompson Cheryl L; Silverman Paula 2015
Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer: results from a large population-based cohort. Wennstig Anna-Karin; Wadsten Charlotta; Garmo Hans; Fredriksson Irma; Blomqvist Carl; Holmberg Lars; Nilsson Greger; Sund Malin 2020
Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study. Chung Il Yong; Lee Jong Won; Moon Hyeong-Gon; Shin Kyung Hwan; Han Wonshik; Son Byung Ho; Ahn Sei-Hyun; Noh Dong-Young 2020
Determinants of newly diagnosed comorbidities among breast cancer survivors. Obi Nadia; Gornyk Daniela; Heinz Judith; Vrieling Alina; Seibold Petra; Chang-Claude Jenny; Flesch-Janys Dieter 2014
Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario. Torres Sofia; Trudeau Maureen; Eisen Andrea; Earle Craig C; Chan Kelvin K W 2015
Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women: A Nationwide Cohort Study. Chien Hsu-Chih; Kao Yang Yea-Huei; Bai Jane P F 2016
Cardiovascular Disease After Aromatase Inhibitor Use. Haque Reina; Shi Jiaxiao; Schottinger Joanne E; Chung Joanie; Avila Chantal; Amundsen Britta; Xu Xiaoqing; Barac Ana; Chlebowski Rowan T 2016
Association between incident cancer and subsequent stroke. Navi Babak B; Reiner Anne S; Kamel Hooman; Iadecola Costantino; Elkind Mitchell S V; Panageas Katherine S; DeAngelis Lisa M 2015
Association of atrial fibrillation and cancer: Analysis from two large population-based case-control studies. Saliba Walid; Rennert Hedy S; Gronich Naomi; Gruber Stephen B; Rennert Gad 2018
Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation. Abdel-Qadir Husam; Thavendiranathan Paaladinesh; Fung Kinwah; Amir Eitan; Austin Peter C; Anderson Geoffrey S; Lee Douglas S 2019
Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ. Yoo Tae-Kyung; Park Sang Hyun; Do Han Kyung; Chae Byung Joo 2021
Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. Thavendiranathan Paaladinesh; Abdel-Qadir Husam; Fischer Hadas D; Camacho Ximena; Amir Eitan; Austin Peter C; Lee Douglas S 2016
Diabetes and cardiovascular disease mortality among a population-based cohort of women with and without breast cancer. Rodriguez Luis A; Bradshaw Patrick T; Parada Humberto; Khankari Nikhil K; Wang Tengteng; Cleveland Rebecca J; Teitelbaum Susan L; Neugut Alfred I; Gammon Marilie D; Rodriguez Luis A; Bradshaw Patrick T; Parada Humberto; Khankari Nikhil K; Wang Tengteng; Cleveland Rebecca J; Teitelbaum Susan L; Neugut Alfred I; Gammon Marilie D 2020
Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population-Based Cohort Study. Franchi Matteo; Trama Annalisa; Merlo Ivan; Minicozzi Pamela; Tarantini Luigi; Garau Donatella; Kirchmayer Ursula; Di Martino Mirko; Romero Marilena; De Carlo Ilenia; Scondotto Salvatore; Apolone Giovanni; Corrao Giovanni; FABIO working group 2020
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. von Minckwitz Gunter; Procter Marion; de Azambuja Evandro; Zardavas Dimitrios; Benyunes Mark; Viale Giuseppe; Suter Thomas; Arahmani Amal; Rouchet Nathalie; Clark Emma; Knott Adam; Lang Istvan; Levy Christelle; Yardley Denise A; Bines Jose; Gelber Richard D; Piccart Martine; Baselga Jose; APHINITY Steering Committee and Investigators 2017
Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Seicean Sinziana; Seicean Andreea; Alan Nima; Plana Juan Carlos; Budd G Thomas; Marwick Thomas H 2013
Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. Boekel Naomi B; Jacobse Judy N; Schaapveld Michael; Hooning Maartje J; Gietema Jourik A; Duane Frances K; Taylor Carolyn W; Darby Sarah C; Hauptmann Michael; Seynaeve Caroline M; Baaijens Margreet H A; Sonke Gabe S; Rutgers Emiel J T; Russell Nicola S; Aleman Berthe M P; van Leeuwen Flora E 2018
Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Khan N F; Mant D; Carpenter L; Forman D; Rose P W 2011
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Vulsteke Christof; Pfeil Alena M; Maggen Charlotte; Schwenkglenks Matthias; Pettengell Ruth; Szucs Thomas D; Lambrechts Diether; Dieudonné Anne-Sophie; Hatse Sigrid; Neven Patrick; Paridaens Robert; Wildiers Hans 2015
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Rabaglio Manuela; Sun Zhuoxin; Maibach Rudolf; Giobbie-Hurder Anita; Ejlertsen Bent; Harvey Vernon J; Neven Patrick; Láng István; Bonnefoi Hervé; Wardley Andrew; Ruepp Barbara; Castiglione Monica; Coates Alan S; Gelber Richard D; Goldhirsch Aron; Colleoni Marco; Thürlimann Beat; Regan Meredith M 2021
Postdiagnostic Calcium Channel Blocker Use and Breast Cancer Mortality: A Population-based Cohort Study. Busby John; Mills Ken; Zhang Shu-Dong; Liberante Fabio Giuseppe; Cardwell Chris R 2018
Long-term mortality from cardiac causes after adjuvant hypofractionated vs. conventional radiotherapy for localized left-sided breast cancer. Chan Elisa K; Woods Ryan; Virani Sean; Speers Caroline; Wai Elaine S; Nichol Alan; McBride Mary L; Tyldesley Scott 2015
A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Lidbrink Elisabet; Chmielowska E; Otremba B; Bouhlel A; Lauer S; Liste Hermoso M; Nüesch E; Shing M; Misra V 2019
Pre- and postdiagnostic diet in relation to mortality among breast cancer survivors in the CPS-II Nutrition Cohort. McCullough Marjorie L; Gapstur Susan M; Shah Roma; Campbell Peter T; Wang Ying; Doyle Colleen; Gaudet Mia M 2016
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. Bonneterre Jacques; Roché Henri; Kerbrat Pierre; Fumoleau Pierre; Goudier Marie-Josèphe; Fargeot Pierre; Montcuquet Philippe; Clavère Pierre; Barats Jean-Claude; Monnier Alain; Veyret Corinne; Datchary Jean; Van Praagh Isabelle; Chapelle-Marcillac Isabelle 2004
[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy]. Jacob J; Belin L; Gobillion A; Daveau-Bergerault C; Dendale R; Beuzeboc P; Campana F; Bollet M-A; Fourquet A; Kirova Y M 2013
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Cadoo Karen A; Morris Patrick G; Cowell Elizabeth P; Patil Sujata; Hudis Clifford A; McArthur Heather L 2016
Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Truong Sandy R; Barry William T; Moslehi Javid J; Baker Emily L; Mayer Erica L; Partridge Ann H 2016
Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors. Cespedes Feliciano Elizabeth M; Chen Wendy Y; Bradshaw Patrick T; Prado Carla M; Alexeeff Stacey; Albers Kathleen B; Castillo Adrienne L; Caan Bette J 2019
Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Ng Huah Shin; Vitry Agnes; Koczwara Bogda; Roder David; McBride Mary L 2019
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. de Azambuja Evandro; Ponde Noam; Procter Marion; Rastogi Priya; Cecchini Reena S; Lambertini Matteo; Ballman Karla; Aspitia Alvaro Moreno; Zardavas Dimitrios; Roca Lise; Gelber Richard D; Piccart-Gebhart Martine; Suter Thomas 2020
Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Henson K E; McGale P; Taylor C; Darby S C 2013
Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study. Carlson Lauren E; Watt Gordon P; Tonorezos Emily S; Chow Eric J; Yu Anthony F; Woods Meghan; Lynch Charles F; John Esther M; Mellemkjӕr Lene; Brooks Jennifer D; Knight Julia A; Reiner Anne S; Liang Xiaolin; Smith Susan A; Bernstein Leslie; Dauer Lawrence T; Cerviño Laura I; Howell Rebecca M; Shore Roy E; Boice John D; Bernstein Jonine L; WECARE Study Collaborative Group 2021
Coronary Event Analysis in Breast Cancer Patients Who Received Breast-Conserving Surgery and Post-Operative Radiotherapy: a Korean Nationwide Cohort Study. Sung Soo-Yoon; Lee Jong Hoon; Yang Ki Hwa; Seo Yunye; Kang Mi Yeon 2020
Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer. Wang Hai-Yan; Yin Bei-Bei; Jia Dan-Yan; Hou Ying-Long 2017
Death causes in breast cancer patients Riihimki, M.; Thomsen, H.; Brandt, A.; Sundquist, J.; Hemminki, K. 2012/03/01
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Guha Avirup; Fradley Michael G; Dent Susan F; Weintraub Neal L; Lustberg Maryam B; Alonso Alvaro; Addison Daniel 2022
Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. He Xuexin; Ji Jiali; Dai Xiaolan; Qdaisat Aiham Z; Esteva Francisco J; Hortobagyi Gabriel N; Yeung Sai-Ching J 2021
Development and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO-RADIAT Score. Kim Do Young; Park Myung-Soo; Youn Jong-Chan; Lee Sunki; Choi Jae Hyuk; Jung Mi-Hyang; Kim Lee Su; Kim Sung Hea; Han Seongwoo; Ryu Kyu-Hyung 2021
Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Matthews Anthony A; Peacock Hinton Sharon; Stanway Susannah; Lyon Alexander Richard; Smeeth Liam; Lund Jennifer L; Bhaskaran Krishnan 2021
Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study. Franchi Matteo; Tritto Roberta; Tarantini Luigi; Navazio Alessandro; Corrao Giovanni 2021
Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer. Connor Avonne E; Schmaltz Chester L; Jackson-Thompson Jeannette; Visvanathan Kala 2021
Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. Gong Inna Y; Yan Andrew T; Earle Craig C; Trudeau Maureen E; Eisen Andrea; Chan Kelvin K W 2020
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Eiger Daniel; Pondé Noam F; Agbor-Tarh Dominique; Moreno-Aspitia Alvaro; Piccart Martine; Hilbers Florentine S; Werner Olena; Chumsri Saranya; Dueck Amylou; Kroep Judith R; Gomez Henry; Láng István; Rodeheffer Richard J; Ewer Michael S; Suter Thomas; de Azambuja Evandro 2020
A balancing act: racial disparities in cardiovascular disease mortality among women diagnosed with breast cancer. Collin Lindsay J; Troeschel Alyssa N; Liu Yuan; Gogineni Keerthi; Borger Kylee; Ward Kevin C; McCullough Lauren E 2020
Pre- and Post-diagnosis Diabetes as a Risk Factor for All-Cause and Cancer-Specific Mortality in Breast, Prostate, and Colorectal Cancer Survivors: a Prospective Cohort Study. Tao Huan; O'Neil Adrienne; Choi Yunseon; Wang Wei; Wang Junfeng; Wang Yafeng; Jia Yongqian; Chen Xiong 2020
Risk of Ischemic and Hemorrhagic Strokes in Occult and Manifest Cancers. Andersen Klaus Kaae; Olsen Tom Skyhøj 2018
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. Sund Maria; Garcia-Argibay Miguel; Garmo Hans; Ahlgren Johan; Wennstig Anna-Karin; Fredriksson Irma; Lindman Henrik; Valachis Antonis 2021
Association between physical activity and subsequent cardiovascular disease among 5-year breast cancer survivors. Kim Kyae Hyung; Choi Seulggie; Kim Kyuwoong; Chang Jooyoung; Kim Sung Min; Kim Seong Rae; Cho Yoosun; Oh Yun Hwan; Lee Gyeongsil; Son Joung Sik; Park Sang Min 2021
Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. Khosrow-Khavar Farzin; Filion Kristian B; Bouganim Nathaniel; Suissa Samy; Azoulay Laurent 2020
Pre-diagnostic sex hormone levels and survival among breast cancer patients. Kensler Kevin H; Eliassen A Heather; Rosner Bernard A; Hankinson Susan E; Brown Myles; Tamimi Rulla M 2019
Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy? Cho Won Kyung; Park Won; Choi Doo Ho; Cha Hyejung; Nam Seok Jin; Kim Seok Won; Lee Jeong Eon; Yu Jonghan; Im Young-Hyuck; Ahn Jin Seok; Park Yeon Hee; Kim Ji-Yeon 2018
Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Elshof Lotte E; Schmidt Marjanka K; Rutgers Emiel J Th; van Leeuwen Flora E; Wesseling Jelle; Schaapveld Michael 2018
Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ. Veal Christopher Thomas; Hart Vicki; Lakoski Susan G; Hampton John M; Gangnon Ronald E; Newcomb Polly A; Higgins Stephen T; Trentham-Dietz Amy; Sprague Brian L 2017
Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors. Cespedes Feliciano Elizabeth M; Kwan Marilyn L; Kushi Lawrence H; Weltzien Erin K; Castillo Adrienne L; Caan Bette J 2017
3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study). Merzenich Hiltrud; Bartkowiak Detlef; Schmidberger Heinz; Schmidt Marcus; Schwentner Lukas; Wiegel Thomas; Woeckel Achim; Wollschläger Daniel; Blettner Maria 2017
Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases. Passarelli Michael N; Newcomb Polly A; Hampton John M; Trentham-Dietz Amy; Titus Linda J; Egan Kathleen M; Baron John A; Willett Walter C 2016
History of Recreational Physical Activity and Survival After Breast Cancer: The California Breast Cancer Survivorship Consortium. Lu Yani; John Esther M; Sullivan-Halley Jane; Vigen Cheryl; Gomez Scarlett Lin; Kwan Marilyn L; Caan Bette J; Lee Valerie S; Roh Janise M; Shariff-Marco Salma; Keegan Theresa H M; Kurian Allison W; Monroe Kristine R; Cheng Iona; Sposto Richard; Wu Anna H; Bernstein Leslie 2015
Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer. Lash Timothy L; Thwin Soe Soe; Yood Marianne Ulcickas; Geiger Ann M; Bosco Jaclyn; Quinn Virginia P; Field Terry S; Pawloski Pamala A; Silliman Rebecca A 2014
Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Park Catherine K; Li Xiaohong; Starr Jason; Harris Eleanor E R 2011 Sep-Oct
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates Alan S; Keshaviah Aparna; Thürlimann Beat; Mouridsen Henning; Mauriac Louis; Forbes John F; Paridaens Robert; Castiglione-Gertsch Monica; Gelber Richard D; Colleoni Marco; Láng István; Del Mastro Lucia; Smith Ian; Chirgwin Jacquie; Nogaret Jean-Marie; Pienkowski Tadeusz; Wardley Andrew; Jakobsen Erik H; Price Karen N; Goldhirsch Aron 2007
Cardiovascular Disease Mortality Among Breast Cancer Survivors. Bradshaw Patrick T; Stevens June; Khankari Nikhil; Teitelbaum Susan L; Neugut Alfred I; Gammon Marilie D 2016
Mortality of women with ductal carcinoma in situ of the breast: a population-based study from the Girona province, Spain (1994-2013). Roca-Barceló A; Viñas G; Pla H; Carbó A; Comas R; Izquierdo Á; Pinheiro P S; Vilardell L; Solans M; Marcos-Gragera R 2019
Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Offersen Birgitte V; Alsner Jan; Nielsen Hanne M; Jakobsen Erik H; Nielsen Mette H; Krause Mechthild; Stenbygaard Lars; Mjaaland Ingvil; Schreiber Andreas; Kasti Unn-Miriam; Overgaard Jens; Danish Breast Cancer Group Radiation Therapy Committee 2020
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab. Banke Ann; Fosbøl Emil L; Ewertz Marianne; Videbæk Lars; Dahl Jordi S; Poulsen Mikael Kjær; Cold Søren; Jensen Maj-Britt; Gislason Gunnar H; Schou Morten; Møller Jacob E 2019
A Population-Based Study of Cardiovascular Mortality Following Early-Stage Breast Cancer. Abdel-Qadir Husam; Austin Peter C; Lee Douglas S; Amir Eitan; Tu Jack V; Thavendiranathan Paaladinesh; Fung Kinwah; Anderson Geoffrey M 2017
The risk of cardiovascular disease following breast cancer by Framingham risk score. Gernaat Sofie A M; Boer Jolanda M A; van den Bongard Desiree H J; Maas Angela H E M; van der Pol Carmen C; Bijlsma Rhodé M; Grobbee Diederick E; Verkooijen Helena M; Peeters Petra H 2018
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. Wadsten C; Wennstig A-K; Garmo H; Nilsson Greger; Blomqvist Carl; Holmberg Lars; Fredriksson Irma; Wärnberg F; Sund M 2018
Radiation-related heart disease after breast cancer radiation therapy in Korean women. Chang Jee Suk; Ko Byung Kyun; Bae Jeoung Won; Yu Jong-Han; Park Min Ho; Jung Yongsik; Jeon Ye Won; Kim Kyung Hwan; Shin Jaeyong; Suh Chang-Ok; Kim Yong Bae; Korean Breast Cancer Society 2017
Comorbidities and cardiovascular disease risk in older breast cancer survivors. Haque Reina; Prout Marianne; Geiger Ann M; Kamineni Aruna; Thwin Soe Soe; Avila Chantal; Silliman Rebecca A; Quinn Virginia; Yood Marianne Ulcickas 2014
Race differences in cardiovascular disease and breast cancer mortality among US women diagnosed with invasive breast cancer. Troeschel Alyssa N; Liu Yuan; Collin Lindsay J; Bradshaw Patrick T; Ward Kevin C; Gogineni Keerthi; McCullough Lauren E 2019
Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study. Staszewsky Lidia; Robusto Fabio; Lepore Vito; Bisceglia Lucia; Petrarolo Vito; D'Ettorre Antonio; Tognoni Gianni; Latini Roberto 2020
All-Cause and Cardiovascular Disease Mortality Among Breast Cancer Survivors in CLUE II, a Long-Standing Community-Based Cohort. Ramin Cody; Schaeffer Marcy L; Zheng Zihe; Connor Avonne E; Hoffman-Bolton Judith; Lau Bryan; Visvanathan Kala 2021
Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. Simon Michael S; Beebe-Dimmer Jennifer L; Hastert Theresa A; Manson JoAnn E; Cespedes Feliciano Elizabeth M; Neuhouser Marian L; Ho Gloria Y F; Freudenheim Jo L; Strickler Howard; Ruterbusch Julie; Barac Ana; Chlebowski Rowan; Caan Bette 2018
The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study. Abdel-Qadir Husam; Thavendiranathan Paaladinesh; Austin Peter C; Lee Douglas S; Amir Eitan; Tu Jack V; Fung Kinwah; Anderson Geoffrey M 2019
Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. Park Na-Jin; Chang Yuefang; Bender Catherine; Conley Yvette; Chlebowski Rowan T; van Londen G J; Foraker Randi; Wassertheil-Smoller Sylvia; Stefanick Marcia L; Kuller Lewis H 2017
Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. Boekel Naomi B; Schaapveld Michael; Gietema Jourik A; Rutgers Emiel J T; Versteegh Michel I M; Visser Otto; Aleman Berthe M P; van Leeuwen Flora E 2014
Increased risk of arterial thromboembolism in older men with breast cancer. Reiner Anne S; Navi Babak B; DeAngelis Lisa M; Panageas Katherine S 2017
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Wang Shi-Yi; Long Jessica B; Hurria Arti; Owusu Cynthia; Steingart Richard M; Gross Cary P; Chen Jersey 2014
Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series. James Melissa; Swadi Sami; Yi Ma; Johansson Lisa; Robinson Bridget; Dixit Ashutosh 2018
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. Kamaraju Sailaja; Shi Yushu; Smith Elizabeth; Nattinger Ann B; Laud Purushottam; Neuner Joan 2019
No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial. Killander Fredrika; Wieslander Elinore; Karlsson Per; Holmberg Erik; Lundstedt Dan; Holmberg Lars; Werner Linda; Koul Sasha; Haghanegi Mahnaz; Kjellen Elisabeth; Nilsson Per; Malmström Per 2020
Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old Asian women with breast cancer. Lee Chih-Hsin; Zhang Jun-Fu; Yuan Kevin Sheng-Po; Wu Alexander T H; Wu Szu-Yuan 2019
Late cardiac morbidity of adjuvant radiotherapy for early breast cancer - A population-based study. Leung Henry W C; Chan Agnes L F; Muo Chih-Hsin 2016
Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer - A real-world data-based, nationwide classification analysis. Fogarassy György; Vathy-Fogarassy Ágnes; Kenessey István; Kásler Miklós; Forster Tamás 2019
Associations between adjuvant radiotherapy and different causes of death in a German breast cancer cohort. Obi Nadia; Eulenburg Christine; Seibold Petra; Eilber Ursula; Thöne Kathrin; Behrens Sabine; Chang-Claude Jenny; Flesch-Janys Dieter 2018
Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Banke Ann; Fosbøl Emil L; Møller Jacob E; Gislason Gunnar H; Andersen Mads; Bernsdorf Mogens; Jensen Maj-Britt; Schou Morten; Ejlertsen Bent 2018
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. Pinder Mary C; Duan Zhigang; Goodwin James S; Hortobagyi Gabriel N; Giordano Sharon H 2007
Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Rugo Hope S; Brufsky Adam M; Ulcickas Yood Marianne; Tripathy Debu; Kaufman Peter A; Mayer Musa; Yoo Bongin; Abidoye Oyewale O; Yardley Denise A 2013
The Importance of Radiation Dose to the Atherosclerotic Plaque in the Left Anterior Descending Coronary Artery for Radiation-Induced Cardiac Toxicity of Breast Cancer Patients? van den Bogaard Veerle A B; Spoor Daan S; van der Schaaf Arjen; van Dijk Lisanne V; Schuit Ewoud; Sijtsema Nanna M; Langendijk Johannes A; Maduro John H; Crijns Anne P G 2021
Effect of Breast Irradiation on Cardiac Disease in Women Enrolled in BCIRG-001 at 10-Year Follow-Up. Wu S Peter; Tam Moses; Vega Raymond Mailhot; Perez Carmen A; Gerber Naamit Kurshan 2017
Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. Rushton Moira; Lima Isac; Tuna Meltem; Johnson Chris; Ivars Josee; Pritchard Kathy; Hawken Steven; Dent Susan 2020
Trends in the risk of cardiovascular disease in women with breast cancer in a Dutch nationwide cohort study. Buddeke Josefien; Gernaat Sofie A M; Bots Michiel L; van den Bongard Desirée H J G; Grobbee Diederick E; Vaartjes Ilonca; Verkooijen Helena M 2019
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Pivot Xavier; Suter Thomas; Nabholtz Jean Marc; Pierga Jean Yves; Espie Marc; Lortholary Alain; Khayat David; Pauporte Iris; Romieu Gilles; Kramar Andrew; Fumoleau Pierre 2015
Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy. Grellier Adedjouma Noemie; Chevrier Marion; Fourquet Alain; Costa Emilie; Xu Haoping; Berger Frederique; Campana Francois; Laki Fatima; Beuzeboc Philippe; Lefeuvre Delphine; Fournier-Bidoz Nathalie; Kirova Youlia M 2017
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. Rossi Marta; Carioli Greta; Bonifazi Martina; Zambelli Alberto; Franchi Matteo; Moja Lorenzo; Zambon Antonella; Corrao Giovanni; La Vecchia Carlo; Zocchetti Carlo; Negri Eva 2016
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Guarneri Valentina; Lenihan Daniel J; Valero Vicente; Durand Jean-Bernard; Broglio Kristine; Hess Kenneth R; Michaud Laura Boehnke; Gonzalez-Angulo Ana M; Hortobagyi Gabriel N; Esteva Francisco J 2006
Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. Appel Jon M; Zerahn Bo; Møller Susanne; Christensen Heidi M; Søgaard Peter; Ejlertsen Bent; Fogh-Andersen Niels; Jensen Benny V; Nielsen Dorte L 2012
Evaluation of cardiac toxicity of systemic treatments in Moroccan patients followed for localized breast cancer: Prospective observational study of 549 cases. Haffadi Mariam; Tawfiq Nezha; Dakir Meriam; Boughafour Mouna; Bouchbika Zineb; Benchakroun Nadia; Jouhadi Hassan; Sahraoui Souha; Benider Abdelatif; Krikez Ikram; Benmallek Rim; Habbal Rachida 2021
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Batist G; Ramakrishnan G; Rao C S; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair M K; Hoelzer K; Tkaczuk K; Park Y C; Lee L W 2001
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. Dang Chau; Guo Hao; Najita Julie; Yardley Denise; Marcom Kelly; Albain Kathy; Rugo Hope; Miller Kathy; Ellis Matthew; Shapira Iuliana; Wolff Antonio C; Carey Lisa A; Moy Beverly; Groarke John; Moslehi Javid; Krop Ian; Burstein Harold J; Hudis Clifford; Winer Eric P; Tolaney Sara M 2016
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Morris Patrick G; Iyengar Neil M; Patil Sujata; Chen Carol; Abbruzzi Alyson; Lehman Robert; Steingart Richard; Oeffinger Kevin C; Lin Nancy; Moy Beverley; Come Steven E; Winer Eric P; Norton Larry; Hudis Clifford A; Dang Chau T 2013
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Swain S M; Ewer M S; Viale G; Delaloge S; Ferrero J-M; Verrill M; Colomer R; Vieira C; Werner T L; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C; BERENICE Study Group 2018
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Schneider Bryan P; O'Neill Anne; Shen Fei; Sledge George W; Thor Ann D; Kahanic Stephen P; Zander Paul J; Davidson Nancy E 2015
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. Martín Miguel; Ruiz Amparo; Ruiz Borrego Manuel; Barnadas Agustí; González Sonia; Calvo Lourdes; Margelí Vila Mireia; Antón Antonio; Rodríguez-Lescure Alvaro; Seguí-Palmer Miguel Angel; Muñoz-Mateu Montserrat; Dorca Ribugent Joan; López-Vega José Manuel; Jara Carlos; Espinosa Enrique; Mendiola Fernández César; Andrés Raquel; Ribelles Nuria; Plazaola Arrate; Sánchez-Rovira Pedro; Salvador Bofill Javier; Crespo Carmen; Carabantes Francisco J; Servitja Sonia; Chacón José Ignacio; Rodríguez César A; Hernando Blanca; Álvarez Isabel; Carrasco Eva; Lluch Ana 2013
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. Goss Paul E; Ingle James N; Pritchard Kathleen I; Ellis Matthew J; Sledge George W; Budd G Thomas; Rabaglio Manuela; Ansari Rafat H; Johnson David B; Tozer Richard; D'Souza David P; Chalchal Haji; Spadafora Silvana; Stearns Vered; Perez Edith A; Liedke Pedro E R; Lang Istvan; Elliott Catherine; Gelmon Karen A; Chapman Judy-Anne W; Shepherd Lois E 2013
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Mackey John R; Martin Miguel; Pienkowski Tadeusz; Rolski Janusz; Guastalla Jean-Paul; Sami Amer; Glaspy John; Juhos Eva; Wardley Andrew; Fornander Tommy; Hainsworth John; Coleman Robert; Modiano Manuel R; Vinholes Jeferson; Pinter Tamas; Rodríguez-Lescure Alvaro; Colwell Bruce; Whitlock Pierre; Provencher Louise; Laing Kara; Walde David; Price Chris; Hugh Judith C; Childs Barrett H; Bassi Kimberly; Lindsay Mary-Ann; Wilson Véronique; Rupin Matthieu; Houé Vincent; Vogel Charles; TRIO/BCIRG 001 investigators 2013
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. Untch Michael; Fasching Peter A; Konecny Gottfried E; Hasmüller Stephan; Lebeau Annette; Kreienberg Rolf; Camara Oumar; Müller Volkmar; du Bois Andreas; Kühn Thorsten; Stickeler Elmar; Harbeck Nadia; Höss Cornelia; Kahlert Steffen; Beck Thomas; Fett Werner; Mehta Keyur M; von Minckwitz Gunter; Loibl Sibylle 2011
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Extra Jean-Marc; Antoine Eric C; Vincent-Salomon Anne; Delozier Thierry; Kerbrat Pierre; Bethune-Volters Anne; Guastalla Jean-Paul; Spielmann Marc; Mauriac Louis; Misset Jean-Louis; Serin Daniel; Campone Mario; Hebert Christophe; Remblier Céline; Bergougnoux Loïc; Campana Frank; Namer Moïse 2010
Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Ejlertsen Bent; Mouridsen Henning T; Jensen Maj-Britt; Andersen Jørn; Cold Søren; Edlund Per; Ewertz Marianne; Jensen Brita B; Kamby Claus; Nordenskjold Bo; Bergh Jonas 2007
Association Between Serum Human Epididymis Protein 4 Levels and Cardiovascular Events in Obese Patients with Breast Cancer. Wang Li; Hu Nie; Jiang Zhongjun; Luo Ping; Yi Nian; Chen Yanhua; Zhou Ning; Liu Longfei 2021
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Wildiers Hans; Tryfonidis Konstantinos; Dal Lago Lissandra; Vuylsteke Peter; Curigliano Giuseppe; Waters Simon; Brouwers Barbara; Altintas Sevilay; Touati Nathan; Cardoso Fatima; Brain Etienne 2018
Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer. Leoce Nicole M; Jin Zhezhen; Kehm Rebecca D; Roh Janise M; Laurent Cecile A; Kushi Lawrence H; Terry Mary Beth 2021
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. Delaloge Suzette; Piccart Martine; Rutgers Emiel; Litière Saskia; van 't Veer Laura J; van den Berkmortel Franchette; Brain Etienne; Dudek-Peric Aleksandra; Gil-Gil Miguel; Gomez Patricia; Hilbers Florentine S; Khalil Zaman; Knox Susan; Kuemmel Sherko; Kunz Georg; Lesur Anne; Pierga Jean-Yves; Ravdin Peter; Rubio Isabel T; Saghatchian Mahasti; Smilde Tineke J; Thompson Alastair M; Viale Giuseppe; Zoppoli Gabriele; Vuylsteke Peter; Tryfonidis Konstantinos; Poncet Coralie; Bogaerts Jan; Cardoso Fatima; MINDACT investigators and the TRANSBIG Consortium 2020
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction. Nowsheen Somaira; Aziz Khaled; Park Jae Yoon; Lerman Amir; Villarraga Hector R; Ruddy Kathryn Jean; Herrmann Joerg 2018
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience. Testore Franco; Milanese Simona; Ceste Marco; de Conciliis Enrico; Parello Giuseppe; Lanfranco Claudio; Manfredi Roberto; Ferrero Gianfranco; Simoni Carlotta; Miglietta Loredana; Ferro Silvia; Giaretto Lorena; Bosso Giuseppina 2008
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. von Minckwitz Gunter; Puglisi Fabio; Cortes Javier; Vrdoljak Eduard; Marschner Norbert; Zielinski Christoph; Villanueva Cristian; Romieu Gilles; Lang István; Ciruelos Eva; De Laurentiis Michele; Veyret Corinne; de Ducla Sabine; Freudensprung Ulrich; Srock Stefanie; Gligorov Joseph 2014
Timing of trastuzumab and risk of cardiac dysfunction in HER2 positive early breast cancer patients Vazdar et al
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Freedman Rachel A; Vaz-Luis Ines; Barry William T; Lii Huichuan; Lin Nancy U; Winer Eric P; Keating Nancy L 2014
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. International Breast Cancer Study Group; Pagani Olivia; Gelber Shari; Price Karen; Zahrieh David; Gelber Richard; Simoncini Edda; Castiglione-Gertsch Monica; Coates Alan S; Goldhirsch Aron 2004
Incident Cardiovascular Disease Among Adults With Cancer Paterson D. Ian; Wiebe Natasha; Cheung Winson Y.; Mackey John R.; Pituskin Edith; Reiman Anthony; Tonelli Marcello; null null 2022/03/01
Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors Reding Kerryn W.; Cheng Richard K.; Vasbinder Alexi; Ray Roberta M.; Barac Ana; Eaton Charles B.; Saquib Nazmus; Shadyab Aladdin H.; Simon Michael S.; Langford Dale; Branch Mary; Caan Bette; Anderson Garnet 2022/03/01
Risk of heart disease following treatment for breast cancer - results from a population-based cohort study. Yang Haomin; Bhoo-Pathy Nirmala; Brand Judith S; Hedayati Elham; Grassmann Felix; Zeng Erwei; Bergh Jonas; Bian Weiwei; Ludvigsson Jonas F; Hall Per; Czene Kamila 2022
Outdoor ambient air pollution and breast cancer survival among California participants of the Multiethnic Cohort Study. Cheng Iona; Yang Juan; Tseng Chiuchen; Wu Jun; Conroy Shannon M; Shariff-Marco Salma; Lin Gomez Scarlett; Whittemore Alice S; Stram Daniel O; Le Marchand Loïc; Wilkens Lynne R; Ritz Beate; Wu Anna H 2022
Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study. Liou Lathan; Kaptoge Stephen; Dennis Joe; Shah Mitul; Tyrer Jonathan; Inouye Michael; Easton Douglas F; Pharoah Paul D P 2021

Downloadable Data Content

Files
  • XLSX Project Data